Skip to main content
. 2017 Jun 27;11:81–95. doi: 10.2147/BTT.S93954

Figure 3.

Figure 3

Clinical profiling of patients to inform consideration of mepolizumab therapy.

Notes: aMarkers of Th2 inflammation (indirect measures of eosinophilic inflammation). bNICE recommends a review of response to treatment after 12 months. cThis is based on clinical judgment.

Abbreviations: NICE, National Institute for Health and Care Excellence; OCS, oral corticosteroid; sc, subcutaneous.